Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Int. j. cardiovasc. sci. (Impr.) ; 34(4): 411-419, July-Aug. 2021. tab, graf
Article in English | LILACS | ID: biblio-1286822

ABSTRACT

Abstract Background Sex-specific pathology of coronary artery disease (CAD) has not been recognized. Women with obstructive or nonobstructive CAD associated with traditional risk factors have similar events; no studies have explored both populations in association with genetic markers. Objective To evaluate the DD genotype in overweight menopausal women and its association with CAD and traditional risk factors. Method This cross-sectional study included 356 menopausal women who underwent coronary angiography as CAD assessment. The patients' DNA was extracted and polymorphisms were detected with a single polymerase chain reaction assay. Two groups were formed based on luminal lesions (normal [n = 134] or pathological [n = 222]) with a cutoff value > 30%, considering overweight and age. The chi-square test, Student's t-test, and multivariate logistic regression were performed as appropriate (p < 0.05) using the following variables: overweight, diabetes, hypertension, dyslipidemia, smoking status, sedentary lifestyle, and a family history of CAD. Results The mean age of the sample was 63 + 8 years, and the mean BMI was 28 + 5 kg/m2. The DD genotype was slightly more prevalent in the pathological group (30.2% vs. 21.6%, p = 0.079), but this significantly changed when BMI > 25 was considered (33% vs. 18%, p = 0.012). In multivariate analysis with two threshold levels (> 50 and > 60 years), diabetes was significantly associated with CAD in both models (p = 0.021 vs. 0.009) but the genotype was only associated with younger age (p = 0.034). Conclusion These data support an association between atherosclerosis and the renin-angiotensin system in overweight menopausal women that is dependent on the age at which the ischemic event occurs.


Subject(s)
Humans , Female , Coronary Artery Disease/etiology , Genetic Markers , Atherosclerosis/enzymology , Menopause , Cross-Sectional Studies , Retrospective Studies , Diabetes Mellitus , Overweight , Heart Disease Risk Factors , Genotype
2.
Clin Sci (Lond) ; 135(15): 1845-1858, 2021 08 13.
Article in English | MEDLINE | ID: mdl-34269800

ABSTRACT

OBJECTIVE: The mechanisms involved in NOX5 activation in atherosclerotic processes are not completely understood. The present study tested the hypothesis that lysophosphatidylcholine (LPC), a proatherogenic component of oxLDL, induces endothelial calcium influx, which drives NOX5-dependent reactive oxygen species (ROS) production, oxidative stress, and endothelial cell dysfunction. APPROACH: Human aortic endothelial cells (HAEC) were stimulated with LPC (10-5 M, for different time points). Pharmacological inhibition of NOX5 (Melittin, 10-7 M) and NOX5 gene silencing (siRNA) was used to determine the role of NOX5-dependent ROS production in endothelial oxidative stress induced by LPC. ROS production was determined by lucigenin assay and electron paramagnetic spectroscopy (EPR), calcium transients by Fluo4 fluorimetry, and NOX5 activity and protein expression by pharmacological assays and immunoblotting, respectively. RESULTS: LPC increased ROS generation in endothelial cells at short (15 min) and long (4 h) stimulation times. LPC-induced ROS was abolished by a selective NOX5 inhibitor and by NOX5 siRNA. NOX1/4 dual inhibition and selective NOX1 inhibition only decreased ROS generation at 4 h. LPC increased HAEC intracellular calcium, important for NOX5 activation, and this was blocked by nifedipine and thapsigargin. Bapta-AM, selective Ca2+ chelator, prevented LPC-induced ROS production. NOX5 knockdown decreased LPC-induced ICAM-1 mRNA expression and monocyte adhesion to endothelial cells. CONCLUSION: These results suggest that NOX5, by mechanisms linked to increased intracellular calcium, is key to early LPC-induced endothelial oxidative stress and pro-inflammatory processes. Since these are essential events in the formation and progression of atherosclerotic lesions, the present study highlights an important role for NOX5 in atherosclerosis.


Subject(s)
Atherosclerosis/enzymology , Endothelial Cells/drug effects , Lysophosphatidylcholines/toxicity , NADPH Oxidase 5/metabolism , Oxidative Stress/drug effects , Reactive Oxygen Species/metabolism , Atherosclerosis/pathology , Calcium/metabolism , Calcium Signaling , Cell Adhesion , Cells, Cultured , Coculture Techniques , Endothelial Cells/enzymology , Endothelial Cells/pathology , Enzyme Activation , Enzyme Inhibitors/pharmacology , Humans , Intercellular Adhesion Molecule-1/genetics , Intercellular Adhesion Molecule-1/metabolism , Monocytes/metabolism , NADPH Oxidase 5/antagonists & inhibitors , NADPH Oxidase 5/genetics , RNA Interference
3.
Curr Pharm Biotechnol ; 17(4): 347-64, 2016.
Article in English | MEDLINE | ID: mdl-26696017

ABSTRACT

The usefulness of selective inhibitors of phosphodiesterase 5 (PDE5) is well known, first for the treatment of male erectile dysfunction and more recently for pulmonary hypertension. The discovery that PDE5 is present in the systemic artery endothelium and smooth muscle cells led investigators to test the extra sexual effects of sildenafil, the first and most investigated PDE5 inhibitor, in diseases affecting the systemic arteries. Cumulative data from experimental and clinical studies have revealed beneficial effects of sildenafil on systemic arterial hypertension and its target organs, such as the heart, kidneys and vasculature. An important effect of sildenafil is reduction of hypertension and improvement of endothelial function in experimental models of hypertension and hypertensive subjects. Interestingly, in angiotensin-dependent hypertension, its beneficial effects on endothelial and kidney dysfunctions seem to at least in part be caused by its ability to decrease the levels of angiotensin II and increase angiotensin 1-7, in addition to improving nitric oxide bioavailability and diminishing reactive oxygen species. Another remarkable finding on the effects of sildenafil comes from studies in apolipoprotein E knockout mice, a model of atherosclerosis that closely resembles human atherosclerotic disease. In this review, we focus on the promising beneficial effects of sildenafil for treating systemic high blood pressure, especially resistant hypertension, and the endothelial dysfunction that is present in hypertension and atherosclerosis.


Subject(s)
Atherosclerosis/drug therapy , Hypertension/drug therapy , Phosphodiesterase 5 Inhibitors/therapeutic use , Animals , Arteries/drug effects , Arteries/enzymology , Atherosclerosis/enzymology , Endothelial Cells/metabolism , Humans , Nitric Oxide/metabolism
4.
Cad. saúde pública ; Cad. Saúde Pública (Online);31(3): 496-506, 03/2015. tab
Article in English | LILACS | ID: lil-744841

ABSTRACT

This study analyzes the available evidence on the adequacy of economic evaluation for decision-making on the incorporation or exclusion of technologies for rare diseases. The authors conducted a structured literature review in MEDLINE via PubMed, CRD, LILACS, SciELO, and Google Scholar (gray literature). Economic evaluation studies had their origins in Welfare Economics, in which individuals maximize their utilities based on allocative efficiency. There is no widely accepted criterion in the literature to weigh the expected utilities, in the sense of assigning more weight to individuals with greater health needs. Thus, economic evaluation studies do not usually weigh utilities asymmetrically (that is, everyone is treated equally, which in Brazil is also a Constitutional principle). Healthcare systems have ratified the use of economic evaluation as the main tool to assist decision-making. However, this approach does not rule out the use of other methodologies to complement cost-effectiveness studies, such as Person Trade-Off and Rule of Rescue.


El objetivo fue sistematizar las evidencias disponibles sobre la pertinencia de utilizar la evaluación económica para la incorporación/exclusión de tecnología en enfermedades raras. Se realizó una revisión sistemática de la literatura en MEDLINE vía PubMed, CRD, LILACS, SciELO y Google Académico (literatura gris). Los estudios de evaluación económica se originan de la Economía del Bienestar, en la que los individuos maximizan sus utilidades, basándose en la eficiencia de asignación. No existe un criterio ampliamente aceptado para examinar las utilidades, a fin de dar más peso a los individuos con mayores necesidades. Generalmente, los estudios no equilibran asimétricamente las utilidades, todas son consideradas iguales, lo que en Brasil es también un principio constitucional. Los sistemas de salud han ratificado el uso de la evaluación económica como la principal herramienta para ayudar en la toma de decisiones. Sin embargo, este abordaje no excluye el uso de otras metodologías complementarias a los estudios de coste-efectividad, como la técnica de compensación personal o la regla del rescate.


O objetivo deste estudo foi analisar as evidências disponíveis sobre a adequação do uso de avaliação econômica sobre incorporação/exclusão de tecnologias para doenças raras. Foi realizada uma revisão estruturada da literatura, nas bases MEDLINE, via PubMed, CRD, LILACS, SciELO e Google Acadêmico (literatura cinzenta). Os estudos de avaliação econômica têm origem na Economia do Bem-Estar, na qual os indivíduos maximizam suas utilidades, fundamentando-se na eficiência alocativa. Não há um critério amplamente aceito para ponderar as utilidades esperadas, no sentido de dar mais peso aos indivíduos com maiores necessidades em saúde. Geralmente não se ponderam assimetricamente as utilidades; todas são tratadas de forma igualitária, que, no caso brasileiro, também é um princípio constitucional. Os sistemas de saúde têm ratificado o uso de avaliação econômica como principal instrumento para auxiliar na tomada de decisão. No entanto, essa postura não exclui o uso de outras metodologias complementares aos estudos de custo-efetividade, como Person Trade-Off e regra de resgate.


Subject(s)
Animals , Humans , Mice , Atherosclerosis/enzymology , Atherosclerosis/pathology , Foam Cells/enzymology , Matrix Metalloproteinases/metabolism , Aortic Rupture/etiology , Aortic Rupture/prevention & control , Atherosclerosis/complications , Atherosclerosis/immunology , Foam Cells/pathology , Gene Expression Regulation, Enzymologic , Lipid Metabolism , Models, Immunological , Matrix Metalloproteinases/genetics , Myocardial Infarction/complications , Myocardial Infarction/enzymology , Myocardial Infarction/immunology , Myocardial Infarction/pathology , Myocytes, Smooth Muscle/pathology , Tissue Inhibitor of Metalloproteinases/immunology , Tissue Inhibitor of Metalloproteinases/metabolism
5.
Curr Opin Lipidol ; 25(2): 148-53, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24535282

ABSTRACT

PURPOSE OF REVIEW: Epigenetic mechanisms of transcriptional regulation in atherosclerosis have gained an increasing interest in recent years. We focus on the relevance of DNA methylation, a well characterized epigenetic modification of the genome, as a biomarker and underlying mechanism of atherosclerosis. RECENT FINDINGS: A growing number of loci have been identified, which are good candidate biomarkers for atherosclerosis and provide novel insights into the molecular changes taking place in the diseased vessel. Understanding the global change in DNA methylation during atherosclerosis remains a challenge. Novel unfolding research avenues include the interplay between genetic variants and DNA methylation patterns, and the role of long noncoding RNAs as epigenetic regulators. SUMMARY: Epigenetics continues to represent a promising area of research in atherosclerosis. The full exploitation of cutting edge epigenomics will be decisive to define whether epigenetics will contribute to lower the burden of cardiovascular diseases.


Subject(s)
Atherosclerosis/genetics , Atherosclerosis/metabolism , DNA Methylation , Epigenesis, Genetic , Epigenomics/methods , Atherosclerosis/enzymology , DNA (Cytosine-5-)-Methyltransferase 1 , DNA (Cytosine-5-)-Methyltransferases/metabolism , Genetic Markers/genetics , Humans
6.
Ann Vasc Surg ; 27(7): 964-71, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23993112

ABSTRACT

BACKGROUND: We searched for any relationship between Chlamydophila pneumoniae, Mycoplasma pneumoniae, matrix metalloproteinase 9 (MMP-9), and tissue inhibitor of metalloproteinase 1 (TIMP-1) in aneurysmatic atherosclerotic lesions, and whether this relationship differed from that in atherosclerotic nonaneurysmatic lesions. METHODS: Twenty-eight tissue samples paired by age and sex were grouped as follows: group 1 included 14 nonaneurysmal atherosclerotic fragments obtained from abdominal aortas collected from necropsies; group 2 included 14 aneurysmatic atherosclerotic aortic fragments obtained from patients during corrective surgery. Immunohistochemistry reactions were evaluated for C pneumoniae, M pneumoniae, MMP-9, and TIMP-1 antigens. Both groups were compared using the Mann-Whitney test, and the correlations among variables were obtained using the Spearman correlation test. P ≤ 0.05 was considered statistically significant. RESULTS: C pneumoniae and M pneumoniae antigens were detected in 100% of cases. A higher amount of C pneumoniae (P = 0.005), M pneumoniae (P = 0.002), and MMP-9 (P = 0.021) was found in adventitia of group 2 with aneurysm. A positive correlation was found in the aneurysm group, as follows: intima C pneumoniae versus adventitia thickness (r = 0.70; P = 0.01), media C pneumoniae versus adventitia C pneumoniae (r = 0.75; P = 0.002), intima C pneumoniae versus media C pneumoniae (r = 0.8; P = 0.00), and adventitia C pneumoniae versus intima M pneumoniae (r = 0.54; P = 0.05); negative correlations were as follows: adventitia thickness and adventitia M pneumoniae (r = -0.65; P = 0.01), media MMP-9 and media thickness (r = -0.55; P = 0.04), TIMP-1 media versus adventitia C pneumoniae (r = -0.86; P = 0.00), and TIMP-1 media versus M pneumoniae intima (r = -0.67; P = 0.03). Nonaneurysmal atherosclerotic group 1 results are as follows: adventitia C pneumoniae versus TIMP-1 media (r = 0.75; P = 0.01) and media C pneumoniae and adventitia C pneumoniae (r = 0.59; P = 0.03). CONCLUSIONS: The present work favors a role for coinfection of both M pneumoniae and C pneumoniae in the development of aortic atherosclerotic aneurysm, with increased adventitial inflammation, inhibition of TIMP-1 activity, and increased collagen degradation.


Subject(s)
Aneurysm, Infected/enzymology , Aorta/enzymology , Aortic Aneurysm/enzymology , Atherosclerosis/enzymology , Chlamydophila Infections/enzymology , Coinfection , Matrix Metalloproteinase 9/analysis , Pneumonia, Mycoplasma/enzymology , Tissue Inhibitor of Metalloproteinase-1/analysis , Adventitia/enzymology , Adventitia/microbiology , Aged , Aneurysm, Infected/diagnosis , Aneurysm, Infected/microbiology , Aneurysm, Infected/surgery , Aorta/microbiology , Aorta/pathology , Aortic Aneurysm/diagnosis , Aortic Aneurysm/microbiology , Aortic Aneurysm/surgery , Atherosclerosis/diagnosis , Chlamydophila Infections/diagnosis , Chlamydophila Infections/microbiology , Chlamydophila Infections/surgery , Chlamydophila pneumoniae/isolation & purification , Dilatation, Pathologic , Female , Humans , Immunohistochemistry , Male , Middle Aged , Mycoplasma pneumoniae/isolation & purification , Pneumonia, Mycoplasma/diagnosis , Pneumonia, Mycoplasma/microbiology , Pneumonia, Mycoplasma/surgery
7.
Rev. méd. Maule ; 28(2): 88-98, dic. 2012. ilus
Article in Spanish | LILACS | ID: lil-679622

ABSTRACT

Reactive oxygen species have emerged as important molecules in cardiovascular function. Recent research has shown that the NADPH oxidases are important sources of superoxide in vascular cells and myocytes. The NADPH oxidases vascular share some, but not all, of the characteristics of the enzyme in neutrophils, both produce superoxide, which is metabolized to hydrogen peroxide, at the same time these reactive oxygen species serve as second messengers activate multiple intracellular signalling pathways. NADPH oxidases are essential in the physiological response of vascular cellsto pathological states such as atherosclerosis, and are functionally relevant in activation and recruitment of platelets. Recent studies suggest a key role for NADPH oxidase in the formation of a specific product from the oxidation of arachidonic acid, and a potential role in the process of recruitment of platelets. Taking into account these characteristics and evidence of the involvement of the NADPH oxidases in cardiovascular diseases as the thrombosis, inhibition of this enzymatic system appears as a promising therapy to treat and prevent these diseases.


Subject(s)
Humans , Atherosclerosis/enzymology , Reactive Oxygen Species , NADPH Oxidases/metabolism , Blood Platelets/enzymology , Platelet Activation/physiology , Antioxidants , Isoprostanes , Polyphenols
8.
Rev Med Chil ; 140(3): 373-8, 2012 Mar.
Article in Spanish | MEDLINE | ID: mdl-22689120

ABSTRACT

Endothelial lipase (EL) is synthetized by endothelial cells and its main substrates are lipoprotein phospholipids. Over expression of EL reduces high density lipoprotein (HDL) cholesterol and phospholipids, in vivo and in vitro. Inhibition of the enzyme achieves the opposite effects. The synthesis of the enzyme is regulated by interleukin 1 and tumor necrosis factor a. These inflammatory cytokines play a role in diabetes and vascular disease. An increase in vascular mechanical forces, that play a role in atherogenesis, also increase the synthesis of EL. There is expression of EL in endothelial cells, macrophages and muscle cells of atherosclerotic lesions of coronary arteries of humans. This evidence leads to the suspicion that EL plays a role in atherogenesis. There are also higher plasma levels of EL in subjects with type 2 diabetes, who are especially susceptible to the development of vascular lesions. Therefore the inhibition of EL could play an important role in HDL metabolism and could be a new therapeutic strategy for the prevention of atherosclerosis.


Subject(s)
Atherosclerosis/enzymology , Diabetes Mellitus, Type 2/enzymology , Endothelium, Vascular/enzymology , Lipase/metabolism , Humans , Lipase/physiology
9.
Rev. méd. Chile ; 140(3): 373-378, mar. 2012. tab
Article in Spanish | LILACS | ID: lil-627653

ABSTRACT

Endothelial lipase (EL) is synthetized by endothelial cells and its main substrates are lipoprotein phospholipids. Over expression of EL reduces high density lipoprotein (HDL) cholesterol and phospholipids, in vivo and in vitro. Inhibition of the enzyme achieves the opposite effects. The synthesis of the enzyme is regulated by interleukin 1 and tumor necrosis factor a. These inflammatory cytokines play a role in diabetes and vascular disease. An increase in vascular mechanical forces, that play a role in atherogenesis, also increase the synthesis of EL. There is expression of EL in endothelial cells, macrophages and muscle cells of atherosclerotic lesions of coronary arteries of humans. This evidence leads to the suspicion that EL plays a role in atherogenesis. There are also higher plasma levels of EL in subjects with type 2 diabetes, who are especially susceptible to the development of vascular lesions. Therefore the inhibition of EL could play an important role in HDL metabolism and could be a new therapeutic strategy for the prevention of atherosclerosis.


Subject(s)
Humans , Atherosclerosis/enzymology , /enzymology , Endothelium, Vascular/enzymology , Lipase/metabolism , Lipase/physiology
10.
Recent Pat Cardiovasc Drug Discov ; 6(1): 42-54, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21208158

ABSTRACT

Matrix metalloproteinases (MMPs) have a pivotal role in the natural history of atherosclerosis and its cardiovascular consequences. Non-selective MMP inhibition with doxycycline appears as a potential strategy to reduce the residual risk observed in patients already at intensive lipid lowering strategies. However, specific MMPs have different and even contradicting roles in the natural history of atherosclerosis, rendering broad spectrum MMP inhibition an important yet somewhat simplistic approach towards residual risk reduction in coronary atherosclerosis. Overall, the balance of non-selective MMP inhibition might shift to the favorable side in particular settings such as in acute coronary syndromes, where in addition to its potential plaque stabilization properties, doxycycline shows promise in preventing ischemia-reperfusion injury and left ventricular remodeling. Nevertheless, to date, most animal models used do not represent advanced coronary atherosclerosis seen in humans, and large and well-designed clinical studies are lacking. We discuss the available evidence and recent patents supporting the role of doxycycline in atherosclerosis.


Subject(s)
Atherosclerosis/drug therapy , Cardiovascular Agents/therapeutic use , Doxycycline/therapeutic use , Matrix Metalloproteinase Inhibitors , Protease Inhibitors/therapeutic use , Animals , Atherosclerosis/enzymology , Atherosclerosis/pathology , Evidence-Based Medicine , Humans , Matrix Metalloproteinases/metabolism , Patents as Topic , Signal Transduction/drug effects , Translational Research, Biomedical , Treatment Outcome
11.
Clin Biochem ; 43(4-5): 416-23, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19850020

ABSTRACT

OBJECTIVE: To characterize the lipid-related atherogenic risk factors in iron deficiency anaemia (IDA) patients. DESIGN AND METHODS: Twenty IDA women were compared to healthy age-matched controls. Lipoprotein profile, cholesteryl ester transfer protein (CETP), paraoxonase (PON) 1 and lipoprotein-associated phospholipase A(2) (LpPLA(2)) activities and plasma levels of oxidized-LDL were evaluated. RESULTS: Triglycerides were higher (median [range]) (1.0 [0.5-1.9] vs. 0.7 [0.5-1.5] mmol/L, p<0.05) and HDL-C lower (mean + or - SD) (1.3 + or - 0.3 vs. 1.6 + or - 0.4 mmol/L, p<0.01) in the patients group. CETP (197 + or - 29% vs. 151 + or - 29% mL(-1) h(-1), p<0.001), PON 1 (122 + or - 17 vs. 140 + or - 33 micromol mL(-1) min(-1), p<0.05) and LpPLA(2) (9.6 + or - 2.0 vs. 8.1 + or - 1.7 micromol mL(-1) h(-1), p<0.05) activities were different in IDA women. No difference was observed in oxidized-LDL. Haemoglobin correlated negatively with triglycerides (r=-0.35, p<0.05), CETP (r=-0.62, p<0.001) and LpPLA(2) (r=-0.34, p<0.05), while ferritin was positively associated with HDL-C (r=0.39, p<0.05) and inversely with CETP (r=-0.49, p<0.005). CONCLUSION: The alterations in lipoprotein profile, CETP, PON 1 and LpPLA(2) activities described in the present study indicate that non-treated IDA might represent a proatherogenic state.


Subject(s)
1-Alkyl-2-acetylglycerophosphocholine Esterase/metabolism , Anemia, Iron-Deficiency/blood , Anemia, Iron-Deficiency/complications , Aryldialkylphosphatase/metabolism , Atherosclerosis/complications , Cholesterol Ester Transfer Proteins/metabolism , Lipoproteins/blood , Anemia, Iron-Deficiency/enzymology , Atherosclerosis/blood , Atherosclerosis/enzymology , Case-Control Studies , Female , Humans , Middle Aged
12.
Biofactors ; 31(2): 77-98, 2007.
Article in English | MEDLINE | ID: mdl-18806312

ABSTRACT

Extracellular nucleotides and nucleosides act as signaling molecules involved in a wide spectrum of biological effects. Their levels are controlled by a complex cell surface-located group of enzymes called ectonucleotidases. There are four major families of ectonucleotidases, nucleoside triphosphate diphosphohydrolases (NTPDases/CD39), ectonucleotide pyrophosphatase/phosphodiesterases (E-NPPs), alkaline phosphatases and ecto-5'-nucleotidase. In the last few years, substantial progress has been made toward the molecular identification of members of the ectonucleotidase families and their enzyme structures and functions. In this review, there is an emphasis on the involvement of NTPDase and 5'-nucleotidase activities in disease processes in several tissues and cell types. Brief background information is given about the general characteristics of these enzymes, followed by a discussion of their roles in thromboregulatory events in diabetes, hypertension, hypercholesterolemia and cancer, as well as in pathological conditions where platelets are less responsive, such as in chronic renal failure. In addition, immunomodulation and cell-cell interactions involving these enzymes are considered, as well as ATP and ADP hydrolysis under different clinical conditions related with alterations in the immune system, such as acute lymphoblastic leukemia (ALL), B-chronic lymphocytic leukemia (B-CLL) and infections associated with human immunodeficiency virus (HIV). Finally, changes in ATP, ADP and AMP hydrolysis induced by inborn errors of metabolism, seizures and epilepsy are discussed in order to highlight the importance of these enzymes in the control of neuronal activity in pathological conditions. Despite advances made toward understanding the molecular structure of ectonucleotidases, much more investigation will be necessary to entirely grasp their role in physiological and pathological conditions.


Subject(s)
5'-Nucleotidase/physiology , Antigens, CD/physiology , Apyrase/physiology , Blood Coagulation/physiology , Adenosine/physiology , Adenosine Triphosphate/metabolism , Animals , Antigens, CD/pharmacology , Apyrase/pharmacology , Atherosclerosis/blood , Atherosclerosis/enzymology , Blood Platelets/physiology , Cell Communication/physiology , Demyelinating Diseases/enzymology , Epilepsy/enzymology , Humans , Metabolism, Inborn Errors/enzymology , Metabolism, Inborn Errors/physiopathology , Myocardial Infarction/blood , Myocardial Infarction/enzymology , Neoplasms/diet therapy , Neoplasms/enzymology , Platelet Activation/physiology , Platelet Aggregation/drug effects , Seizures/enzymology , Signal Transduction , Tamoxifen/therapeutic use , Thrombosis/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL